11/29/2016 - AMCP submits comments in response to PQA Endorsement Consideration of Two New Performance Measures: Concurrent Use of Opioids and Benzodiazepines and Adherence to Non-Infused Disease Modifying Agents Use to Treat Multiple Sclerosis.
11/29/2016 - AMCP submits comments in response to PQA Endorsement Consideration of Two New Performance Measures: Concurrent Use of Opioids and Benzodiazepines and Adherence to Non-Infused Disease Modifying Agents Use to Treat Multiple Sclerosis.